Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.

Authors	Harald Kropshofer, Dieter A Häring, Ludwig Kappos, David Leppert, Jens Kuhle
Journal	Neurology (Neurology) Vol. 98 Issue 11 Pg. 470-471 (03 15 2022) ISSN: 1526-632X [Electronic] United States
PMID	35288475 (Publication Type: Letter, Comment)
Chemical References	Immunologic Factors Natalizumab
Topics	Humans Immunologic Factors (adverse effects) Intermediate Filaments Multiple Sclerosis (blood) Multiple Sclerosis, Relapsing-Remitting (blood, drug therapy) Natalizumab (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!